The China Resources Pharmaceutical Group Limited Group ("CR Pharma") (stock code: 3320.HK) was officially added to the FTSE Global Equity Index Series (Large Cap), FTSE All-World Index and FTSE Global All Cap Index effective on June 19, 2017. It proves the market confidence in the outlook for CR Pharma and the market recognition of its business performance.
As the global leading index standard, FTSE index has been widely adopted by investors in North America, Europe, and Asia as the benchmark of performance and the basis for derivatives and other index-gauged products.
In only eight short months since its IPO in Hong Kong in October 2016, CR Pharma has been included in the Hang Seng Composite Large-cap Index, the Hang Seng China Healthcare Index and the Hang Seng Healthcare Index. In 2016, the operating revenue of CR Pharma reached HK$156.7 billion, a year-on-year increase of 13.9% in RMB terms. Excluding non-recurring profit and loss and the fluctuation of RMB exchange rate, the profit attributable to owners of the Company is HK$2.82 billion, an increase close to 20% on year-on-year basis.
In line with industry policies, CR Pharma has been optimizing its portfolio and innovation offerings in 2017. CR Pharma adopted the Two-Invoice System, aimed at improving transparency in drug prices and eliminating excessive profit margins associated with the multi-tier distribution model. CR Pharma has taken this opportunity to revisit its distribution network for optimization. The company has strategically entered into the field of bio-medicine, fully exploited the synergy among various business units and sped up extensive development and international cooperation. These practices will bring a steady and sustainable growth of significant business segments in the long term, and more value to our investors.